Opendata, web and dolomites

AptaCheck

Bioelectronic lab-on-a-chip for point-of-care detection of infectious agents

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AptaCheck project word cloud

Explore the words cloud of the AptaCheck project. It provides you a very rough idea of what is the project "AptaCheck" about.

minutes    biosensor    financing    jobs    simplicity    biochips    overcome    markets    instability    identifications    chip    qr    wifi    drawbacks    detection    detecting    aptacheck    automated    portability    market    flu    time    electronic    patients    equipped    enter    drug    accuracy    handling    quality    cumulative    platform    diagnosis    data    revenues    cutting    clinical    scanner    fast    antibody    complete    poc    3bn    74    approved    preventing    2020    linked    chain    industrial    disposable    aptachek    industry    action    direct    reader    observation    easily    display    outbreaks    accurate    pathogens    clinics    immediately    departments    lower    secure    versatile    obligatory    hospitals    care    special    edge    15    skills    house    diagnostics    mover    elisa    groundbreaking    optimisation    adequately    lab    first    scalable    downstream    communication    parallel    point    isolated    transfer    2024    clinically    infections    turnover    samples    later    pcr    wireless    semi    advantage    consolidated    strategic    microbiological    aptamer    600    8m    eventual    human    infectious    supply    approvals    manufacturing    gastroenteritis    beats   

Project "AptaCheck" data sheet

The following table provides information about the project.

Coordinator
SOLSTEN DIAGNOSTICS AS 

Organization address
address: HEDEAGER 40
city: AARHUS N
postcode: 8200
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://solsten-diag.com
 Total cost 2˙254˙187 €
 EC max contribution 1˙577˙931 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SOLSTEN DIAGNOSTICS AS DK (AARHUS N) coordinator 1˙577˙931.00

Map

 Project objective

AptaCheck is a groundbreaking platform for detecting infections pathogens in human samples: the first aptamer-based biosensor platform with lab-quality accuracy, allowing a fast, clinically accurate diagnosis. AptaCheck will overcome the drawbacks of the antibody based point-of-care (POC) devices (lower accuracy and instability). Aptacheck is equipped with a hand-held reader, which comprises a display for direct observation, a QR scanner for identifications, and WiFi for data transfer. AptaCheck beats the state of the art: - Cost: The disposable chip will cost the end user €10 - Time: Turnover-time is less than 15 minutes including sample handling - Accuracy: AptaCheck will be more reliable than ELISA and comparable to PCR - Simplicity: No special equipment or skills are needed - Portability: The hand-held reader and biochips can be used at the point of care - Communication: AptaCheck will be linked to electronic lab systems via wireless communication - Action: Patients can adequately be treated; Infectious patients can immediately be isolated preventing eventual outbreaks - Versatile: AptaCheck can easily be adapted to detection of new pathogens. We consolidated our first-mover advantage in in-house, robust, semi-automated, cutting-edge, up-scalable industrial production process for the biochips. AptaChek will be approved and deployed in clinical microbiological departments in hospitals. Later it will be deployed at clinics, drug manufacturing industry, etc. With Phase II financing, AptaCheck will enter a €3.3bn market for gastroenteritis diagnostics in 2020, and produce €74.8m in cumulative revenues for FLU and 600 new jobs in FLU and the supply chain by 2024. FLU seeks funding to complete the system optimisation for pre-clinical testing and for the obligatory clinical approvals. In parallel to this, we will secure a key strategic downstream distribution partner, and investigate new markets and applications in the diagnostics sector for the AptaCheck platform.

 Deliverables

List of deliverables.
Portfolio of communication material Other 2020-02-18 15:41:04

Take a look to the deliverables list in detail:  detailed list of AptaCheck deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "APTACHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "APTACHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More  

HIL PT System (2017)

Revolutionary, cost effective, spatially efficient, proton therapy system for cancer treatment.

Read More